Bristol-Myers Squibb Company Celegne Contingent Value Rights (CELG.R)

Bristol-Myers Squibb Company Celegne Contingent Value Rights (CELG.R $0.09)
- $0.09 P/E (TTM): 20.04X Cap: $117.30B
- View CELG.R Profile
- View Questions on CELG.R

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

Bristol-Myers Squibb Company Celegne Contingent Value Rights (CELG.R $0.09)
- $0.09 P/E (TTM): 20.04X Cap: $117.30B
- View CELG.R Profile
- View Questions on CELG.R

Q: Is there going to be value left in these rights? A very tiny fraction of portfolio left over from BMY buying Celgene. What are my options here and what are your thoughts/suggestions. I thank you in advance.

Read Answer Asked by Tulio on November 09, 2020